AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19662024 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (alpha-adrenergic agonist)
Number of subjects: 50
Study 19662024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16508761 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 18
Study 16508761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16508761 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 18
Study 15096075 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specifically olanzapine)
Number of subjects: 0
Study 15096075 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0
Study 15096075 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 11798851 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic piperacillin/tazobactam
Number of subjects: 63
Study 11798851 — intervention group
Group type: COMPARATOR
Intervention: Timentin (Control)
Number of subjects: 63
Study 11798851 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening group (Domestic piperacillin/tazobactam)
Number of subjects: 63
Study 9726128 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance training program
Number of subjects: 102
Study 8308975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser with shorter pulse duration
Number of subjects: 20
Study 8308975 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser with longer pulse duration
Number of subjects: 20
Study 2508049 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin, 300 mg/kg/day plus tobramycin, 10 and more mg/kg/day for 14 days
Number of subjects: 21
Study 2508049 — intervention group
Group type: COMPARATOR
Intervention: ceftazidime, 150 mg/kg/day for 14 days
Number of subjects: 21
Study 1260780 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 40
Study 30778821 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 118
Study 30778821 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 30851032 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer-based biolimus-eluting stents (BES)
Number of subjects: 1157
Study 30851032 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1157
Study 28605206 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic self-management plan (four educational sessions and three personal home sessions)
Number of subjects: 24
Study 28605206 — intervention group
Group type: COMPARATOR
Intervention: Short manual with asthma information (control group)
Number of subjects: 24
Study 25589624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Veliparib (60 mg orally once daily)
Number of subjects: 75
Study 25589624 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone (50 mg orally once daily)
Number of subjects: 75
Study 23936331 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary betaine excretion in patients with diabetes mellitus (n = 264)
Number of subjects: 2396
Study 23936331 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary betaine excretion
Number of subjects: 2396
Study 23936331 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline betaine excretion
Number of subjects: 2396
Study 23936331 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin
Number of subjects: 2396
Study 21882087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-contrast dose protocol (P(low)): iohexol-350 [0.7 ml/kg body weight (BW)] during 9 s
Number of subjects: 60
Study 21882087 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (P(conv)): iohexol-350 (1.0 ml/kg BW) during 15 s
Number of subjects: 60
Study 18710401 — intervention group
Group type: COMPARATOR
Intervention: Mandibular free-end removable partial denture wearers (group II)
Number of subjects: 28
Study 18710401 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary and mandibular complete denture wearers (group I)
Number of subjects: 28
Study 17266094 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participants
Number of subjects: 40
Study 17266094 — intervention group
Group type: COMPARATOR
Intervention: Trial nonparticipants
Number of subjects: 40
Study 17266094 — intervention group
Group type: COMPARATOR
Intervention: Patients with diabetes
Number of subjects: 40
Study 15193740 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide 80 mg (formulation 1)
Number of subjects: 20
Study 15193740 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide 80 mg (formulation 2)
Number of subjects: 20
Study 11331167 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib capsule po 1 hour before induction of anesthesia
Number of subjects: 0
Study 11331167 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule po 1 hour before induction of anesthesia
Number of subjects: 0
Study 9154397 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terbinafine 1% solution
Number of subjects: 110
Study 9154397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 7700076 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg once daily
Number of subjects: 180
Study 7700076 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 5.0 mg once daily
Number of subjects: 180
Study 7700076 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 3688394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 60
Study 3688394 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 60
Study 3688394 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 3688394 — intervention group
Group type: COMPARATOR
Intervention: Trichloroethylene
Number of subjects: 60
Study 29352454 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 97
Study 29352454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 27001782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating massage of all masseter muscles, tourmaline ceramic on the joint area, and local physical therapy.
Number of subjects: 0
Study 27001782 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine blockade of periarticular area (control group).
Number of subjects: 0
Study 26509174 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C, vitamin E, and zinc supplementation for 8 weeks
Number of subjects: 60
Study 26509174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23437055 — intervention group
Group type: EXPERIMENTAL
Intervention: MYM-V101 vaccine at 10 μg/dose
Number of subjects: 24
Study 23437055 — intervention group
Group type: EXPERIMENTAL
Intervention: MYM-V101 vaccine at 50 μg/dose
Number of subjects: 24
Study 23437055 — intervention group
Group type: EXPERIMENTAL
Intervention: MYM-V101 vaccine (both doses)
Number of subjects: 24
Study 23437055 — intervention group
Group type: EXPERIMENTAL
Intervention: MYM-V101 vaccine (high dose)
Number of subjects: 24
Study 20008820 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered tango dance
Number of subjects: 39
Study 20008820 — intervention group
Group type: COMPARATOR
Intervention: Nonpartnered tango dance
Number of subjects: 39
Study 18834276 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy for complicated grief
Number of subjects: 107
Study 18834276 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of positive emotion as a mediator
Number of subjects: 107
Study 16402602 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexity-based estimators of heart rate variability (detrended fluctuation analysis coefficient, sample entropy, largest Lyapunov exponent)
Number of subjects: 0
Study 16402602 — intervention group
Group type: COMPARATOR
Intervention: Traditional measures of heart rate variability
Number of subjects: 0
Study 12953347 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 3381 (25, 50, 100, 200, 300, 450, and 600 mg)
Number of subjects: 56
Study 12953347 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 3381 (600 mg)
Number of subjects: 56
Study 12953347 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 3381 (various doses)
Number of subjects: 56
Study 12953347 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 3381 (300 and 600 mg)
Number of subjects: 56
Study 12953347 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 3381 (200 mg)
Number of subjects: 56
Study 12953347 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 3381 (300 mg)
Number of subjects: 56
Study 12953347 — intervention group
Group type: COMPARATOR
Intervention: Food ingestion
Number of subjects: 56
Study 10962546 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (20 mg daily subcutaneous injection)
Number of subjects: 251
Study 8722342 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg (BuCy2) preparative regimen
Number of subjects: 26
Study 8722342 — intervention group
Group type: COMPARATOR
Intervention: Standard cyclosporine and methotrexate or cyclosporine and methylprednisolone for GVHD prophylaxis
Number of subjects: 26
Study 8722342 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan and cyclophosphamide (BuCy2)
Number of subjects: 26
Study 1730131 — intervention group
Group type: EXPERIMENTAL
Intervention: Later intervention (LI)
Number of subjects: 205
Study 1730131 — intervention group
Group type: COMPARATOR
Intervention: Early intervention (EI)
Number of subjects: 205
Study 3901832 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour theophylline preparation (Theo-Dur)
Number of subjects: 20
Study 3901832 — intervention group
Group type: COMPARATOR
Intervention: 24-hour theophylline preparation (Theo-24)
Number of subjects: 20
Study 31184720 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Membrane Oxygenation (ECMO)
Number of subjects: 0
Study 31184720 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 29381569 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion therapy (3 mg/kg) administered once a week for 4 consecutive weeks
Number of subjects: 42
Study 29381569 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusions (control group) administered once a week for 4 consecutive weeks
Number of subjects: 42
Study 26361380 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (PSD)
Number of subjects: 16
Study 26361380 — intervention group
Group type: COMPARATOR
Intervention: Full Sleep
Number of subjects: 16
Study 26361380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Sleep Conditions
Number of subjects: 16
Study 25699349 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven 7 ml/kg in 20 mins before induction and 8 ml/kg after induction
Number of subjects: 40
Study 25699349 — intervention group
Group type: COMPARATOR
Intervention: Plasmalyte A 6 ml/kg/h
Number of subjects: 40
Study 25699349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 25699349 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven
Number of subjects: 40
Study 22856218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric solution (7.5 mg levobupivacaine + 50 microg Fentanyl + 1 ml 10% glucose)
Number of subjects: 110
Study 22856218 — intervention group
Group type: COMPARATOR
Intervention: Hypobaric solution (7.5 mg levobupivacaine + 50 microg Fentanyl + 1 ml 0.9% NaCl)
Number of subjects: 110
Study 21313917 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 microg per 4 h up to 3 days)
Number of subjects: 111
Study 21313917 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal suppositories
Number of subjects: 111
Study 18019402 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir at 14.3 mg/kg every 6 hours
Number of subjects: 0
Study 18019402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18019402 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0
Study 16615261 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (intervention group)
Number of subjects: 103
Study 16615261 — intervention group
Group type: COMPARATOR
Intervention: Control group (prior to insulin infusion)
Number of subjects: 103
Study 14669937 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.75% carbohydrate solution
Number of subjects: 9
Study 14669937 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.75% carbohydrate/1.94% protein solution
Number of subjects: 9
Study 14669937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10947748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg x kg(‐1) with neostigmine
Number of subjects: 3
Study 10947748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg x kg(‐1) without neostigmine
Number of subjects: 3
Study 10947748 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg x kg(‐1)
Number of subjects: 3
Study 10947748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg x kg(‐1)
Number of subjects: 3
Study 8773908 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 4 months (Group 1)
Number of subjects: 116
Study 8773908 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 10 months (Group 2)
Number of subjects: 116
Study 8773908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no treatment or different duration)
Number of subjects: 116
Study 8773908 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with interferon
Number of subjects: 116
Study 1537998 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rt‐PA (1.25 mg/kg over 90 min, regimen C)
Number of subjects: 232
Study 1537998 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggerated (60‐min) dosage regimen
Number of subjects: 232
Study 1537998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (accelerated rt‐PA and intravenous urokinase, regimen E)
Number of subjects: 232
Study 1537998 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3‐h dosing regimens
Number of subjects: 232
Study 6462423 — intervention group
Group type: EXPERIMENTAL
Intervention: MS subjects using a semantic encoding strategy
Number of subjects: 22
Study 6462423 — intervention group
Group type: EXPERIMENTAL
Intervention: MS subjects
Number of subjects: 22
Study 6462423 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 22
Study 31291159 — intervention group
Group type: EXPERIMENTAL
Intervention: Loud vocal SPL
Number of subjects: 32
Study 31291159 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous vocal SPL
Number of subjects: 32
Study 29061222 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (IMT) - high-frequency sessions (3 sessions per week)
Number of subjects: 364
Study 29061222 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (IMT) - low-frequency sessions (1 session per week)
Number of subjects: 364
Study 29061222 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (ESC) alone
Number of subjects: 364
Study 29061222 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (IMT)
Number of subjects: 364
Study 25822648 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow MSCs (40 × 10^6 cells, intra-articular injection)
Number of subjects: 30
Study 25822648 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (60 mg, single dose, intra-articular)
Number of subjects: 30
Study 25822648 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow MSCs
Number of subjects: 30
Study 23360149 — intervention group
Group type: EXPERIMENTAL
Intervention: Aft cleat position
Number of subjects: 13
Study 23360149 — intervention group
Group type: COMPARATOR
Intervention: Traditional cleat position
Number of subjects: 13
Study 22086695 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b 1.5μg/kg/wk for 23 months (group 1)
Number of subjects: 18
Study 22086695 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b 1.5μg/kg/wk for 11 months (group 2)
Number of subjects: 18
Study 22086695 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (combined analysis)
Number of subjects: 18
Study 19519822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP+)
Number of subjects: 75
Study 19519822 — intervention group
Group type: COMPARATOR
Intervention: No intervention (IP‐)
Number of subjects: 75
Study 17689947 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate 50/100 microg bd
Number of subjects: 4
Study 17689947 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg bd
Number of subjects: 4
Study 15288592 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg/day plus piperazine-sultosilate 1000 mg/day
Number of subjects: 26
Study 15288592 — intervention group
Group type: COMPARATOR
Intervention: pravastatin 40 mg/day
Number of subjects: 26
Study 11696941 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized criteria for monitoring heart rate and oxygen saturation during gentle human touch (GHT) intervention
Number of subjects: 0
Study 11696941 — intervention group
Group type: COMPARATOR
Intervention: Standard criteria for monitoring heart rate and oxygen saturation
Number of subjects: 0
Study 9441096 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pulmonary tuberculosis (SPT) patients
Number of subjects: 17
Study 9441096 — intervention group
Group type: COMPARATOR
Intervention: Control group (PT)
Number of subjects: 17
Study 9441096 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 17
Study 8202005 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose prednisolone
Number of subjects: 64
Study 3479045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g) administered at 12-hour intervals
Number of subjects: 8
Study 3479045 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 12-hour intervals
Number of subjects: 8
Study 30120004 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual aberration‐correcting IOL (Invidua‐aA; Group A)
Number of subjects: 86
Study 30120004 — intervention group
Group type: COMPARATOR
Intervention: Standard aspheric aberration‐free IOL (Aspira‐aA; Group B)
Number of subjects: 86
Study 27020075 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation treatment (MRT)
Number of subjects: 122
Study 27020075 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 122
Study 26581842 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (oral 20 mg/night for 8 weeks)
Number of subjects: 96
Study 26581842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin for 8 weeks)
Number of subjects: 96
Study 23738908 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of EMLA cream (5% lidocaine 25 mg‐prilocaine 25 mg/g)
Number of subjects: 92
Study 23738908 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of ultrasound gel (placebo)
Number of subjects: 92
Study 20684147 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound ointment (calcipotriene 50 microg/g and betamethasone 0.5 mg/g)
Number of subjects: 24
Study 20684147 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound ointment (calcipotriene 50 microg/g and betamethasone 0.5 mg/g) for 52 weeks
Number of subjects: 24
Study 20684147 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound ointment alternating with calcipotriene four-weekly
Number of subjects: 24
Study 20684147 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 0.5 mg/g (as dipropionate; Diprosone) ointment
Number of subjects: 24
Study 18305085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 42
Study 18305085 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 42
Study 18305085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SES and BMS
Number of subjects: 42
Study 16941299 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 units Botulinum toxin A (BoNT A)
Number of subjects: 25
Study 16941299 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 units Botulinum toxin A (BoNT A)
Number of subjects: 25
Study 16941299 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 12923616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (initial bolus 0.5 micro g/kg and continuous infusion rate of 0.5 micro g/kg per hour)
Number of subjects: 10
Study 12923616 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (initial bolus 0.08 mg/kg and continuous infusion 0.05 mg/kg per hour)
Number of subjects: 10
Study 10875787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BCG vaccination (double-dose)
Number of subjects: 48
Study 10875787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BCG booster vaccination
Number of subjects: 48
Study 10875787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BCG vaccination
Number of subjects: 48
Study 10875787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9083231 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 33
Study 8239321 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 4
Study 8239321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 4
Study 3752219 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposeful activities
Number of subjects: 30
Study 3752219 — intervention group
Group type: COMPARATOR
Intervention: Nonpurposeful activities
Number of subjects: 30
Study 29265833 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 547
Study 29265833 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on symptomatology
Number of subjects: 547
Study 29265833 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on the alliance
Number of subjects: 547